Skip to main content

Table 1 Clinical and pathologic data stratified by endometrioid versus serous histology

From: Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups

  All (N = 47) EAC (N = 34) USC (N = 13) OR (95% CI)b p-value
Age (years) 63.6 ± 11.0 60.9 ± 11.2 70.7 ± 7.0   < 0.01
Parity (number of children) 2 (1, 4) 1 (0,3) 4 (2, 7)   < 0.01
Race/ethnicitya
 White 13 (27.7) 11 (32.4) 2 (15.4) REF 0.08
 Black 14 (29.8) 6 (17.7) 8 (61.5) 7.33 (1.16–46.23)
 Asian 3 (6.4) 3 (8.8) 0 (0) N/A
 Hispanic 8 (19.2) 7 (20.6) 2 (15.4) 1.57 (0.18–13.86)
Race/ethnicitya
 White 13 (33.3) 11 (40.7) 2 (16.7) REF 0.13
 Non-White 26 (66.7) 16 (59.3) 10 (83.3) 3.44 (0.63–18.84)
Pregnancy history
 Nulliparous 11 (23.4) 11 (32.4) 0 (0) REF 0.02
 Parous 36 (76.7) 23 (63.9) 13 (100.0) N/A
 Personal history of malignancy 6 (12.8) 3 (8.82) 3 (23.1) 3.10 (0.54–18.87) 0.33
 Family history of malignancy 29 (61.7) 22 (64.7) 7 (53.9) 0.64 (0.17–2.32) 0.52
Tobacco use
 Never 35 (74.5) 24 (70.6) 11 (84.6) REF 0.62
 Former 9 (19.2) 7 (20.6) 2 (15.4) 0.62 (0.11–3.50)
 Current 3 (6.4) 3 (8.8) 0 (0) N/A
Metastatic disease
 Pelvic lymph nodes 9 (19.2) 4 (11.8) 5 (38.5) 5.00 (1.06–23.65) 0.09
 Para-aortic lymph nodes 8 (17.0) 2 (5.9) 6 (46.2) 8.50 (1.33–54.12)  < 0.01
 Omentum 0 (0) 0 (0) 0 (0) N/A N/A
 Ovaries 6 (12.8) 4 (11.8) 2 (15.4) 1.50 (0.24–9.47) 0.74
 Fallopian tubes 2 (4.3) 0 (0) 2 (15.4) N/A 0.07
 Cervix 17 (36.2) 7 (20.6) 10 (76.9) 12.86 (2.77–59.66)  < 0.01
 Lower uterine segment 2 (4.3) 2 (5.8) 0 (0) N/A  > 0.90
 Lymphovascular invasion 18 (38.3) 11 (32.4) 7 (53.9) 2.44 (0.66–9.00) 0.18
 Cytology 1 (2.1) 1 (2.9) 0 (0) N/A  > 0.90
Myometrial invasion
 0% 5 (10.6) 5 (14.7) 0 (0) REF 0.25
 1–33% 18 (38.3) 13 (38.2) 5 (38.5) 0.38 (0.08–1.93)
 34–66% 14 (29.8) 11 (32.4) 3 (23.1) 0.27 (0.05–1.62)
 67–100% 10 (21.3) 5 (14.7) 5 (38.5) N/A
Stage
 I 23 (48.9) 22 (64.7) 1 (7.7) REF  < 0.01
 II 8 (17.0) 4 (11.8) 4 (30.8) 22.00 (1.92–251.54)
 III 15 (31.9) 7 (20.6) 8 (61.5) 25.14 (2.66–237.62)
 IV 1 (2.1) 1 (2.9) 0 (0) N/A
Stage
 I–II 31 (66.0) 26 (76.5) 5 (38.5) REF 0.02
 III–IV 16 (34.0) 8 (23.5) 8 (61.5) 5.20 (1.32–20.46)
Treatment
 Chemotherapy 25 (53.2) 12 (35.3) 13 (100.0) N/A  < 0.01
 External beam radiation therapy 22 (46.8) 11 (32.4) 11 (84.6) 11.50 (2.17–61.04)  < 0.01
 Brachytherapy 24 (51.1) 14 (41.2) 10 (76.9) 4.76 (1.11–20.50) 0.03
 Recurrence or progression 15 (31.9) 7 (20.6) 8 (61.5) 6.17 (1.53–24.84) 0.01
 Progression free survival (months) 33 (15, 45) 37.5 (24, 48) 15 (5, 26)    < 0.01
Vital status
 Alive 34 (72.3) 27 (79.4) 7 (53.9) REF 0.06
 Dead 4 (8.5) 1 (2.94) 3 (23.1) 11.57 (1.04–128.97)
 Lost to follow-up 9 (19.2) 6 (17.7) 3 (23.1) 1.93 (0.38–9.71)
  1. Data with plus-minus values represent means ± standard deviation, otherwise reported as median (interquartile range). Categorical data are presented as N (%)
  2. EBRT external beam radiation therapy, LVSI positive lymphovascular space invasion
  3. aBased on 39 patients with available race/ethnicity information
  4. bRefers to the odds of individual covariates being associated with serous histology relative to endometrioid histology. N/A values indicate that odds ratios are incalculable as subgroups predict failure perfectly